Last: | $1.21 |
---|---|
Change Percent: | -0.83% |
Open: | $1.22 |
Close: | $1.21 |
High: | $1.29 |
Low: | $1.21 |
Volume: | 222,606 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.21 | $1.22 | $1.21 | $1.29 | $1.21 | 222,606 | 05-31-2024 |
$1.21 | $1.27 | $1.21 | $1.28 | $1.21 | 219,436 | 05-30-2024 |
$1.27 | $1.28 | $1.27 | $1.3 | $1.23 | 166,613 | 05-29-2024 |
$1.27 | $1.22 | $1.27 | $1.29 | $1.21 | 160,331 | 05-28-2024 |
$1.23 | $1.28 | $1.23 | $1.28 | $1.2 | 306,186 | 05-27-2024 |
$1.23 | $1.28 | $1.23 | $1.28 | $1.2 | 306,186 | 05-24-2024 |
$1.27 | $1.3 | $1.27 | $1.34 | $1.25 | 203,955 | 05-23-2024 |
$1.3 | $1.29 | $1.3 | $1.3599 | $1.28 | 149,449 | 05-22-2024 |
$1.31 | $1.25 | $1.31 | $1.39 | $1.24 | 424,168 | 05-21-2024 |
$1.26 | $1.33 | $1.26 | $1.36 | $1.25 | 408,106 | 05-20-2024 |
$1.27 | $1.41 | $1.27 | $1.41 | $1.25 | 471,177 | 05-17-2024 |
$1.4 | $1.43 | $1.4 | $1.44 | $1.38 | 200,503 | 05-16-2024 |
$1.44 | $1.42 | $1.44 | $1.51 | $1.38 | 283,805 | 05-15-2024 |
$1.39 | $1.43 | $1.39 | $1.525 | $1.38 | 456,698 | 05-14-2024 |
$1.42 | $1.44 | $1.42 | $1.45 | $1.4 | 349,498 | 05-13-2024 |
$1.42 | $1.65 | $1.42 | $1.66 | $1.42 | 398,163 | 05-10-2024 |
$1.51 | $1.45 | $1.51 | $1.53 | $1.42 | 638,421 | 05-09-2024 |
$1.39 | $1.86 | $1.39 | $2.39 | $1.36 | 4,230,539 | 05-08-2024 |
$1.67 | $1.75 | $1.67 | $1.75 | $1.61 | 303,395 | 05-07-2024 |
$1.72 | $1.67 | $1.72 | $1.8 | $1.6 | 473,040 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
NYSE Market:
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...
CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday’s session after the company received positive feedback...
Critical milestone achieved—the FDA accepted CEL-SCI’s selection criteria defining the Multikine target population before surgery Selected patient population had 73% survival with Multikine vs. 45% without Multikine based on analysis of completed 928-patient Phase 3 rand...